BRPI0509979A - método para detectar ncrna - Google Patents

método para detectar ncrna

Info

Publication number
BRPI0509979A
BRPI0509979A BRPI0509979-0A BRPI0509979A BRPI0509979A BR PI0509979 A BRPI0509979 A BR PI0509979A BR PI0509979 A BRPI0509979 A BR PI0509979A BR PI0509979 A BRPI0509979 A BR PI0509979A
Authority
BR
Brazil
Prior art keywords
ncrna
detecting
purposes
detect
signature
Prior art date
Application number
BRPI0509979-0A
Other languages
English (en)
Inventor
Jian Han
Original Assignee
Genaco Biomedical Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaco Biomedical Products Inc filed Critical Genaco Biomedical Products Inc
Publication of BRPI0509979A publication Critical patent/BRPI0509979A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/101—Modifications characterised by incorporating non-naturally occurring nucleotides, e.g. inosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/107—Temperature of melting, i.e. Tm
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODO PARA DETECTAR ncRNA é descrito um novo método para a detecção de moléculas de ncRNA. O método divulgado é especialmente útil para a detecção de miRNA e siRNA. O método pode ser usado para gerar um perfil das moléculas de ncRNA presentes em uma amostra. Além disso, usando os métodos da presente divulgação pode ser criada uma assinatura de ncRNA para uma dada doença ou condição. A assinatura de ncRNA pode ser usada para finalidades diagnósticas, finalidades terapêuticas e finalidade de descobrimento de drogas, assim como para outros usos.
BRPI0509979-0A 2004-04-20 2005-04-20 método para detectar ncrna BRPI0509979A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56387704P 2004-04-20 2004-04-20
PCT/US2005/013247 WO2005103298A2 (en) 2004-04-20 2005-04-20 Method for detecting ncrna

Publications (1)

Publication Number Publication Date
BRPI0509979A true BRPI0509979A (pt) 2007-10-16

Family

ID=35197559

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509979-0A BRPI0509979A (pt) 2004-04-20 2005-04-20 método para detectar ncrna

Country Status (10)

Country Link
US (1) US7811759B2 (pt)
EP (1) EP1745150A4 (pt)
JP (1) JP2007533324A (pt)
KR (1) KR20070004957A (pt)
CN (1) CN101056991A (pt)
AU (1) AU2005236044B2 (pt)
BR (1) BRPI0509979A (pt)
CA (1) CA2585525A1 (pt)
NZ (1) NZ551019A (pt)
WO (1) WO2005103298A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2302055T3 (pl) 2004-11-12 2015-02-27 Asuragen Inc Sposoby i kompozycje z wykorzystaniem miRNA oraz cząsteczek inhibitorowych miRNA
CA2603881A1 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
US20060247503A1 (en) * 2005-04-29 2006-11-02 Sellers Orlando Ii Method for predicting a transition to an increased probability of injury
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
JP2007082436A (ja) * 2005-09-20 2007-04-05 Bioinformatics Institute For Global Good Inc 機能性ＲＮＡが制御するターゲットｍＲＮＡの予測・同定方法及びその利用方法
CN102943108B (zh) 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
CN101448958A (zh) 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA2649045C (en) * 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
AU2012216487B2 (en) * 2006-04-03 2015-05-14 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
US7955848B2 (en) 2006-04-03 2011-06-07 Trustees Of Dartmouth College MicroRNA biomarkers for human breast and lung cancer
US8207325B2 (en) 2006-04-03 2012-06-26 Univ. of Copenhagen MicroRNA biomarkers for human breast and lung cancer
EP2369017B8 (en) 2006-07-13 2014-03-12 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
US20080081330A1 (en) * 2006-09-28 2008-04-03 Helicos Biosciences Corporation Method and devices for analyzing small RNA molecules
EP2061901A2 (en) * 2006-10-31 2009-05-27 Noxxon Pharma AG Methods for detection of a single- or double-stranded nucleic acid molecule
AU2007314212B2 (en) * 2006-11-01 2014-05-29 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services MicroRNA expression signature for predicting survival and metastases in Hepatocellular carcinoma
WO2008071384A1 (en) * 2006-12-13 2008-06-19 Roche Diagnostics Gmbh Use of tde for the isolation of nucleic acids
AU2008211142A1 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
CA2690749A1 (en) 2007-06-15 2008-12-24 The Ohio State University Research Foundation Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing
ES2496172T3 (es) 2007-07-31 2014-09-18 The Ohio State University Research Foundation Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
ES2570359T3 (es) 2007-08-03 2016-05-18 Univ Ohio State Res Found Regiones ultraconservadas que codifican ARNnc
ES2562078T3 (es) 2007-08-22 2016-03-02 The Ohio State University Research Foundation Métodos y composiciones para inducir la desregulación de la fosforilación de EphA7 y ERK en leucemias agudas humanas
EP3492594A1 (en) 2007-10-04 2019-06-05 Roche Innovation Center Copenhagen A/S Micromirs
CN103898069A (zh) 2007-10-26 2014-07-02 俄亥俄州立大学研究基金会 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
EP2257647B1 (en) * 2008-02-28 2016-09-14 The Ohio State University Research Foundation Micro rna-based methods and compositions for the diagnosis of gastric cancer
AU2009221064B2 (en) 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
WO2009117418A2 (en) 2008-03-17 2009-09-24 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
AU2009257410B2 (en) 2008-06-11 2014-03-06 Fudan University Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
WO2010033818A2 (en) * 2008-09-19 2010-03-25 Immune Disease Institute, Inc. Mirna targets
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
US20110117559A1 (en) * 2009-11-13 2011-05-19 Integrated Dna Technologies, Inc. Small rna detection assays
CN102803511A (zh) 2009-11-23 2012-11-28 俄亥俄州立大学 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
CN103748236B (zh) 2011-04-15 2018-12-25 约翰·霍普金斯大学 安全测序系统
US9249468B2 (en) 2011-10-14 2016-02-02 The Ohio State University Methods and materials related to ovarian cancer
JP2015501843A (ja) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
CA2866052A1 (en) 2012-01-20 2013-07-25 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
JP6146760B2 (ja) * 2012-02-28 2017-06-14 国立研究開発法人産業技術総合研究所 序列化装置、序列化方法及びプログラム
EP2837695B1 (en) * 2012-04-12 2018-01-10 The University of Tokyo Nucleic acid quantification method, detection probe, detection probe set, and nucleic acid detection method
CN103146688B (zh) * 2012-09-12 2015-05-13 上海长海医院 长链非编码rna作为疾病诊断血液分子标志物的应用
WO2014070462A1 (en) 2012-10-29 2014-05-08 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
US20160024565A1 (en) * 2013-03-13 2016-01-28 Tufts University Fragment complementation of based assays
WO2015123449A2 (en) * 2014-02-12 2015-08-20 Thomas Jefferson University Compositions and methods of using microrna inhibitors
EP2949759B1 (en) 2014-05-27 2017-07-26 Université Paris Sud 11 Multiplexed homogeneous oligonucleotide detection
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CN110225747A (zh) * 2016-12-05 2019-09-10 莱古路斯治疗法股份有限公司 用于治疗多囊肾病的方法
WO2019067092A1 (en) 2017-08-07 2019-04-04 The Johns Hopkins University METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
WO2021006279A1 (en) * 2019-07-08 2021-01-14 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988617A (en) * 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1990001564A1 (en) 1988-08-09 1990-02-22 Microprobe Corporation Methods for multiple target analyses through nucleic acid hybridization
CA2095611A1 (en) * 1990-11-14 1992-05-15 Jennifer Kyoko Ishii Non-isotopic detection of nucleic acids using a polystyrene support-based sandwich hybridization assay and compositions useful therefor
AU9240898A (en) * 1997-07-04 1999-01-25 Gist-Brocades B.V. Process for the modification of toxic and/or off-flavoured compounds
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
WO2001013119A1 (en) * 1999-08-17 2001-02-22 Luminex Corporation Encapsulation of fluorescent particles
AU2001278517A1 (en) * 2000-08-03 2002-02-18 F. Hoffman-La Roche Ag Nucleic acid binding compounds containing pyrazolo(3,4-d)pyrimidine analogues of purin-2,6-diamine and their uses
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1409735A4 (en) * 2001-06-25 2005-10-05 Georgia Tech Res Inst DOUBLE-RESONANCE ENERGY TRANSFER NUCLEIC PROBES
US7459145B2 (en) * 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
WO2004039962A2 (en) * 2002-10-30 2004-05-13 Pointilliste, Inc. Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
EP2295604B1 (en) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features

Also Published As

Publication number Publication date
AU2005236044B2 (en) 2010-01-07
JP2007533324A (ja) 2007-11-22
EP1745150A2 (en) 2007-01-24
WO2005103298A3 (en) 2005-12-15
KR20070004957A (ko) 2007-01-09
EP1745150A4 (en) 2008-02-27
CN101056991A (zh) 2007-10-17
WO2005103298A2 (en) 2005-11-03
WO2005103298A9 (en) 2007-05-18
AU2005236044A1 (en) 2005-11-03
US7811759B2 (en) 2010-10-12
CA2585525A1 (en) 2005-11-03
US20080166707A1 (en) 2008-07-10
NZ551019A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
BRPI0509979A (pt) método para detectar ncrna
BRPI0906858B8 (pt) métodos in vitro para detectar a presença de uma célula de câncer em um indivíduo e para identificar uma assinatura específica de tumor em um indivíduo tendo câncer.
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112015030287A2 (pt) ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas
BR112014024219A8 (pt) Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit
BR112016009099A2 (pt) Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
BRPI0917871A2 (pt) agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
BR112013027124A2 (pt) método e sistema para analisar características de tecido
EP3239305A3 (en) Use of microvesicles in diagnosis and prognosis of medical diseases and conditions
DOP2011000045A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
BR112012009481A2 (pt) método e dispositivo para detectar uma pluralidade de alvos em uma amostra biológica, e, kit para detectar uma pluralidade de alvos múltiplos em uma amostra biológica
BRPI0714563A2 (pt) Infidelidade de transcrição, detecção e usos das mesmas
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
BR112015006284A2 (pt) cpmf como um biomarcador para diabetes e métodos associados
BR112013023970A2 (pt) composição farmacêutica, dispositivo, inibidor de hdac, kit, método de pré-tratamento de um ser humano que sofre de câncer e método de avaliação do efeito de uma substância sobre a sensibilidade a chop de linhagens celulares
Shao et al. CSF miR-16 expression and its association with miR-16 and serotonin transporter in the raphe of a rat model of depression
WO2008074029A3 (en) Protein profile for osteoarthritis
BR112014029808A2 (pt) método para testar o efeito de uma etapa de produção ou etapas de produção ou a eficácia de uma etapa de purificação ou etapas de purificação na presença ou na natureza de moléculas pró-inflamatórias em polímeros de glicose ou hidrolisados dos mesmos; e método otimizado para produzir ou purificar polímeros de glicose ou hidrolisados dos mesmos
WO2013188437A3 (en) Ex vivo methods to identify circulating drug metabolites with drug interaction potential
CY1121260T1 (el) Μεθοδος για ληψη ενος διαπιδυσιμου εκχυλισματος λευκοκυτταρων
Ettala et al. Erectile dysfunction cannot be used in primary screening of pre-diabetes
EP1988164A4 (en) METHOD FOR TESTING THE SENSITIVITY OF SOLIC CANCER AGAINST A TYROSINE KINASE INHIBITOR AND CORRESPONDING TEST REQUIREMENTS
Wu et al. Biomarker predictive ibrutinib response using profiled ABC-DLBCL patient derived xenografts
BR112013032132A2 (pt) "uso de peptidase da família calicreína, de agente que aumenta a sua expressão ou de células que apresentam expressão ou atividade de rheb reduzida para prevenção ou tratamento de diabetes e distúrbio metabólico e aumento da sensibilidade à insulina, bem como métodos para determinar se composto de teste é agente terapêutico provável no tratamento de diabetes"

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.